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rob.cooper@lhch.nhs.ukAbstractHypertrophic cardiomyopathy (HCM) is a highly heterogeneous disease with varied patterns
of hypertrophy. Basal septal hypertrophy and systolic anterior motion (SAM) of the mitral
valve (MV) are the key pathophysiological components to left ventricular outflow tract
(LVOT) obstruction in HCM. LVOT is associated with higher morbidity and mortality in
patients with HCM. Percutaneous septal reduction therapy with alcohol septal ablation
(ASA) can lead to a significant improvement in left ventricle haemodynamics, patient
symptoms and perhaps prognosis. ASA delivers pure alcohol to an area of myocardium
via septal coronary arteries; this creates damage to tissue akin to a myocardial infarction.
The basal septal myocardium involved in SAM–septal contact is the target for this iatrogenic
infarct. Appropriate patient selection and accurate delivery of alcohol are critical to safe and
effective ASA. Securing the correct diagnosis and ensuring suitable cardiac anatomy are
essential before considering ASA. Pre-procedural planning and intra-procedural imaging
guidance are important to delivering precise damage to the desired area. The procedure is
performed worldwide and is generally safe; the need for a pacemaker is the most prominent
complication. It is successful in the majority of patients but room for improvement exists.
New techniques have been proposed to perform percutaneous septal reduction. We present
a review of the relevant pathophysiology, current methods and a summary of available
evidence for ASA. We also provide a glimpse into emerging techniques to deliver
percutaneous septal reduction therapy.Key Words
" hypertrophic obstructive
cardiomyopathy
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" non-surgical septal reduction
therapyBackground
Hypertrophic cardiomyopathy (HCM) is an inherited
disease characterised by otherwise unexplained hyper-
trophy of the myocardium. It is transmitted in an autosomal
dominant pattern with variable penetrance, with an
estimated phenotypic prevalence of one in 500 (1). HCM is
a highly heterogeneous disease with varied patterns of
hypertrophy. The prevalence of left ventricular outflow
tract (LVOT) obstruction in HCM is 20–30% at rest (2)and up to 70% with provocation (3). LVOT obstruction
is associated with greater levels of dyspnoea, a greater
incidence of stroke and higher mortality (2).LVOT obstruction pathophysiology
Basal septal hypertrophy and systolic anterior motion
(SAM) of the mitral valve (MV) are the key components to
LVOT obstruction in HCM. Recent magnetic resonancewww.echorespract.com
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Figure 1
Effects of ASA on basal septum. (A and B) A 42-year-old male with a septum
of 29 mm, severe SAM of the MV and LVOT gradient of 102 mmHg before
ASA. See Videos 1 and 2. (C and D) The septum post-ASA; there is a
reduction in size of the basal septum. Videos 3 and 4 show reduction in
systolic excursion of the septum and SAM. The LVOT gradient post-ASA
was 10 mmHg.
Video 1
Parasternal long-axis view of a 42-year-old male with
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have highlighted a significantly longer anterior leaflet
when compared with controls, this results in coaptation
with the posterior leaflet towards its midpoint, leaving a
redundant tip (4). This is now suggested to be part of the
HCM phenotype.
The asymmetric hypertrophy (ASH) of the basal
septum leads to a narrowed left ventricle (LV) outflow
tract; this causes rapid acceleration of blood flow apical of
the MV. Venturi drag effects through the narrowed LVOT
are thought to contribute to pulling the MV apparatus
towards the septum. This does not explain SAM of the MV
observed at low velocities, hence it is not the sole
pathophysiological process. The septal hypertrophy also
causes abnormal posteriorly directed flow through the LV
(5). This flow circulates around the MV and back towards
the LVOT, catching the redundant anterior MV leaflet
tip. The MV then moves towards, and in severe cases
contacts, the hypertrophied septum. Once mitral–septal
contact occurs, the LVOT orifice is narrowed further and
greater obstruction to flow develops, resulting in a higher
pressure difference. This pressure difference forces the
leaflet further against the septum, further narrowing the
orifice, exacerbating the haemodynamic abnormalities.
This establishes an amplifying feedback loop until systole
is complete. The greater the length of time the AMVL is
in contact with the septum, the higher the pressure
difference (5).
This obstruction has multiple deleterious effects
including reduction of forward cardiac output, mitral
regurgitation of varying degrees, and load-dependent
diastolic dysfunction leading to an increase in LV end-
diastolic pressure and subsequent coronary flow abnormal-
ities. These factors contribute to symptoms of dyspnoea,
chest pain, pre-syncope and syncope (6, 7, 8).HOCM, the basal septum at LVOT level measures 27 mm. In
systole, the MV apparatus (including the posterior leaflet)
moves anteriorly towards the septum. The long anterior
leaflet contacts the septum in the LVOT causing severe
obstruction to flow out of the LV. Download Video 1 via
http://dx.doi.org/10.1530/ERP-14-0058-v1.
Video 2
An area of the basal septum at the LVOT level has an
infarct. The myocardium has shrunk and measures just
13 mm. The LVOT has widened. The SAM of the MV
apparatus is now mild with minimal movement of the
anterior leaflet towards the LVOT. Download Video 2 via
http://dx.doi.org/10.1530/ERP-14-0058-v2.Alcohol septal ablation
The critical event in this pathophysiological cycle is
SAM–septal contact. This therefore becomes the target
for percutaneous septal reduction therapy.
Alcohol septal ablation (ASA) damages the basal
interventricular septum by inducing a localised infarc-
tion with trans-coronary alcohol injection. The LVOT
widens, and the basal septum does not move towards
the MV in systole (Fig. 1, Videos 1 and 2). This reduces
SAM and allows a greater area for blood to escape from
the heart (Video 2). There is a reduction in intra-cavity
pressure in the LV and hence gradient. The effects can
continue to improve for months afterwards. This canwww.echorespract.compartly be explained by the change in diastolic function,
the drop in LVOT gradient has been shown to reduce
left ventricular hypertrophy distant from the LVOT and
therefore cardiac mass (9, 10); this shows that part of
the hypertrophy in HOCM is after load dependent and
not entirely genetically pre-determined.R26
Video 4
Apical long axis view 6 months post alcohol ablation.
Note reduced septal width and SAM. Download Video 4
via http://dx.doi.org/10.1530/ERP-14-0058-v4.
Video 3
Parasternal long axis view 6 months post alcohol ablation.
The mass of myocardium at the proximal basal septum is
reduced. There is less systolic anterior motion of the
anterior mitral valve leaflet which no longer contact the
septum. Download Video 3 via http://dx.doi.org/10.1530/
ERP-14-0058-v3.
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Appropriate patient selection is imperative to the per-
formance of effective and safe ASA. The treating team must
complete comprehensive clinical assessment. Although
no restrictions are placed upon age of patient, it is
generally recommended that it is inappropriate to perform
ASA in children (11). The long-term risk of ventricular
arrhythmia remains unclear, and providing a potentially
arrhythmic scar in children is discouraged. If deemed
appropriate for ASA, it is then necessary to perform
detailed investigation of cardiac anatomy and haemody-
namics and explore functional impairment.Clinical assessment
Assess symptom burden The primary reason for
performing ASA currently is to improve symptomatology.
There has been some suggestion that removing LVOT
gradients with ASA improves prognosis, but this is not yet
secure and should not be the driver to treatment (12, 13).
Patients must report NYHA class III dyspnoea (11, 14).
Exceptions can be made for patients with class II dyspnoea,
disabling non-arrhythmogenic pre-syncope/syncope or
chest pain without revascularisation options. Patients must
be symptomatic despite optimisation ofnegatively inotropic
medications such as b-blockers, verapamil or disopyramide
before consideration of septal reduction therapy.
Rule out phenocopies The operator must be secure in
a diagnosis of genetically determined HCM. It is essential
to ensure that the patient does not suffer from any
pathology that is amenable to alternative therapies before
performing a deliberately destructive procedure.
Trial of right ventricular apical pacing Some
patients with HCM already have a cardiac rhythm
management device in situ. In these patients, a trial ofwww.echorespract.comdual-chamber right ventricular (RV) apical pacing with a
short atrioventricular delay should be performed to assess
effects on LVOT gradient and symptoms. Pacing can be
effective in a small proportion of patients (15, 16, 17, 18).
It is not currently indicated as first-line treatment (11, 14).Assessment of cardiac anatomy and haemodynamics
Assessment of LVOT gradient There must be a
demonstrable LVOT gradient to correct in order for ASA
to be effective. It has been stated in the ACCF/AHA and
recent ESC guidelines for the management of HCM that a
gradient of R50 mmHg is required for a patient to derive
benefit from treatment (11, 14).
A gradient is calculated using the modified Bernoulli
equation based on flow velocities measured with continu-
ous-wave Doppler through the LVOT. The aortic valve and
LVOT should be assessed to ensure that there is no stenosis
or sub-aortic band responsible for the increased velocities.
The envelope shape attributable to LVOT obstruction in
SAM-mediated HOCM is typically scimitar shaped with
late-flow acceleration. This is related to the pathophysiology
described earlier, where the amplifying feedback loop causes
accelerated late pressures and hence increased blood
velocity (Fig. 1). It is important to ensure that the Doppler
signal is not measuring the mitral regurgitation flow that is
often associated with SAM; the flow of MR often has high
velocities and can lead to erroneously high LVOT gradient
calculations (Fig. 2). Pulsed wave Doppler can be used to
localise the flow acceleration point, as those with mid-cavity
gradients do not derive as much benefit from ASA (19).
ASA can also be effective for those with a minimal
gradient at rest but with a marked increase with Valsalva
manoeuvre or exercise (20). Dobutamine causes an
apparent LVOT gradient in the normal heart and should
not be used in these circumstances (21).
Septal size The basal septum should be R15 mm.
There is a risk of ventricular septal defect with iatrogenic
infarct in those with a septum !15 mm. Although rare,
VSDs have been reported as a complication from ASA (22).
The ESC guidelines suggest that a septum ofR17 mm as a
minimum measurement for alcohol ablation to be
considered (14). The benefit of ASA in those with a septum
O30 mm is not clear. It is generally recommended that
myectomy is a more suitable option in these patients (11).
MV and papillary muscle anatomy MV abnorma-
lities are relatively common in HCM (23). Primary disease
of the MV should prompt a surgical referral. Cardiac MRIR27
Figure 2
(A) A continuous-wave Doppler trace through the LVOT and aortic valve.
Note the late acceleration and the subsequent scimitar-shaped envelope.
The peak velocity in this patient was 3.1 m/s. (B) A CW trace through
the posteriorly directed MR observed as a result of SAM and failure of
coaptation of the MV leaflets. This has a more symmetrical shape and high
velocities of 7.9 m/s. If this velocity were used to incorrectly calculate a
gradient, the value would be 250 mmHg. Compare this with the correct
calculation of just 38 mmHg.
Table 1 Clinical and diagnostic criteria of patients must fulfil
before progression to ASA.
Category Criteria for progression to ASA
Diagnosis Clinician must be satisfied that the
pathology is genetically determined
hypertrophic cardiomyopathy in the
absence of other causes of LVH
Symptom status NYHA III dyspnoea
NYHA II with non-arrhythmic
pre-syncope or chest pain
Medications Symptoms refractory to an adequate trial
of negatively inotropic medications
LVOT gradient R50 mmHg at rest, Valsalva manoeuvre
or with exercise stress
LVOT gradient must be due to SAM of
the MV. Causes such as sub-aortic
band and anomalous papillary muscle
architecture must be ruled out
Septal size R15 mm in diastole
Alternative
indication for
surgery
Rule out coronary artery disease,
sub-aortic band or MV abnormalities
requiring surgical intervention
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no abnormal papillary muscle anatomy such as anterior
displacement or direct insertion into valve leaflets that
would also require surgical correction (24).
Rule out alternative pathologies requiring
surgical intervention Significant co-morbid cardiac
disease requiring surgery such as coronary artery disease,
sub-aortic bands or MV abnormalities should prompt a
surgical referral. Combined operative therapy incorporat-
ing septal myectomy is preferred in these circumstances.
RV apical pacing Trial of RV pacing if dual-chamber device
already in situ
Functional testing O50% predicted FEV1 and FVC on PFTs
!90% predicted peak VO2 on CPEX
testing
Cardiac restriction on CPEX testingFunctional assessment
Pulmonary function tests Pulmonary disease as the
prime driver to dyspnoea must be excluded beforewww.echorespract.comprogressing to ASA. Removal of the LVOT gradient in
these patients is less likely to alleviate symptoms (25).
Classification of Rmoderate COPD by global initiative
for chronic obstructive lung disease (GOLD) severity scale
should prompt optimisation of lung disease management
before consideration of ASA (26). A restrictive pattern on
PFTs should prompt further pulmonary investigations.
Cardiopulmonary exercise testing CPEX allows an
accurate assessment of the true physical restriction along
with providing information on the contribution of
pulmonary and cardiac diseases. There must be a baseline
abnormal limit to exertion to correct before considering
ASA (Table 1).Pre-procedural investigation
In order to achieve satisfactory assessment of suitability for
ASA, the investigations in Table 2 are completed.ASA: the procedure
ASA should be performed by experienced operators; the
learning curve in ASA can require the performance of at
least 40 procedures (27). This was re-enforced in theR28
Table 2 Investigations performed in the workup of patients proposed for ASA.
Category Test Rationale
Haematological U&Es Secondary organ dysfunction
Often abnormal in phenocopies (HTN, Anderson-Fabry, infiltration)
CK Rule out syndromes such as myotonic dystrophy
FBC Rule out anaemia as a cause of dyspnoea
a-galactosidase Consider in cases where there is clinical suspicion of Anderson-Fabry disease
ECG 12-lead ECG Help distinguish phenocopies:
Small QRS – infiltrative myocardial disease
Excessively large QRS – Pompe’s, Danon’s syndromes
1st degree HB – storage disease
AV block – infiltration, Anderson-Fabry
Pre-excitation – Pompe’s, Danon’s syndromes
Extreme axis deviation – Noonan’s syndromes
24-h ECG Consideration of SCD risk and potential for ICD implantation before ASA
24-h BP monitor Consider in cases where a phenocopy of hypertensive heart disease is suspected
Imaging Echocardiogram Assess:
Septal size
Extent of SAM
LVOT gradient extent and localisation, rest and with Valsalva manoeuvre
Diastolic function
Cardiac MRI Assess:
Septal size and distribution of hypertrophy
Presence of HCM variant such as abnormal direct papillary muscle insertion into MV
leaflets, antero-apical displacement of anterior papillary muscle, sub-aortic band
Assess pre-existing scar; risk of SCD and comparison of iatrogenic scar location
post-ASA
CT coronary
angiography
Plan access to septal arteries that supply target myocardium
Rule out significant coronary artery disease that will require CABG
Functional PFTs Rule out significant lung disease as the primary driver to dyspnoea
CPEX Assess:
Functional capacity (baseline to compare with post-ASA)
Primary cause of dyspnoea
Prognostic implications
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operator must have experience of at least 20 procedures
or work in a centre with a cumulative procedural volume
of 50 patients (11).
Arterial access is secured and a guidecath manoeuvred
to the coronary arteries. Simultaneous monitoring of LV
and central aortic pressures can be performed using and
end-hole catheter placed at the LV apex and a guidecath
in the ascending aorta. This will give continuous LVOT
gradient readings throughout the procedure. This usually
requires two arterial access points but diagnostic
procedures can be carried out with one puncture using a
pressure wire sited in the LV apex. LVOT gradient should
be measured at rest and following an ectopic beat for
the Brockenbrough–Braunwald–Morrow phenomenon.
Sometimes a high ectopic burden or runs of ventricular
tachycardia from catheter irritation prevent continuous
monitoring of the gradient.
A venous sheath should be sited to allow insertion of a
temporary pacing wire (TPW) at the RV apex. Septal pacingwww.echorespract.commust be avoided as early activation of the septum can
increase LVOT obstruction.
Heparin is used to prevent thromboembolic compli-
cation. A guidewire is advanced to the septal artery of
choice. This may be a sub-branch of a septal artery as these
vessels often supply both the right and left septal myocardia.
An over-the-wire balloon is then advanced into the septal
artery. Once inflated, this then creates a secure, hollow
channel from the operator to the target myocardium.
Myocardial contrast echocardiography is then used
to demonstrate the area of myocardium supplied by the
chosen vessel. Contrast should be injected into the
chosen septal artery with continuous echocardiographic
screening. An obvious opacification of the area of the
septum involved in the contact point for SAM will be
observed if the artery is the correct choice (Fig. 3). Multiple
projections are required to ensure the correct distribution
in three dimensions.
If contrast is observed elsewhere, an alternative artery
will need to be explored (Fig. 4).R29
Figure 3
Myocardial contrast echocardiography. Echocardiographic contrast is
injected into a chosen septal artery with continuous echocardiographic
screening. Localisation of the contrast can be observed in the basal septum
in the parasternal long-axis (A), apical 5-chamber (B) and apical long-axis
(C) views. (D) A parasternal short-axis view with contrast visible at
11 O’clock. This is required as an additional view to ensure that the chosen
vessel does not supply an area too inferior or anterior in the septum.
Contrast should highlight the SAM–septal contact area.
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angiographic contrast (0.5 ml) injected into the septal
artery beyond balloon occlusion to ensure no spill back
into the parent artery or collateral connection to other
septal or major epicardial vessels.
Once the target artery has been satisfactorily ident-
ified, a small volume (1–3 ml) of absolute alcohol is
injected slowly in small increments. Analgesia can be
given, as injection of alcohol can cause some discomfort.
The volume of alcohol injected will depend on the area of
myocardium opacified with contrast injection. There is
evidence to suggest that small doses (1–2 ml) of alcohol
can have equally effective results as large (2–4 ml) doses
(28, 29). Balloon occlusion should be maintained for at
least 5 min. A final angiographic image is taken to show
the septal branch no-reflow and rule out any unwanted
coronary artery damage.
The patient is kept under coronary care supervision for
24–48 h with the TPW in situ. If no complete heart block is
present at that time, it can be removed. Temporary
permanent pacemakers can be used for up to 4 weeks to
allow intrinsic conduction to recover. This may reducewww.echorespract.comthe need for permanent system implantation. Hospital
stay is 4–5 days if no complication is observed.Peri-procedural complications of ASA
The most prominent complication associated with ASA is
the need for a permanent pacemaker. The risk in large
multicentre observations remains around 10% (22, 25, 30,
31, 32). Lower doses of alcohol and increased operator
experience appear to reduce this risk. While the ramifica-
tions of a pacemaker should not be dismissed, we must
bear in mind that RV apical pacing can be an effective
treatment to reduce LVOT gradients in some patients.
Others require ICD implantation due to risk of SCD. The
use of cardiac rhythm management devices in this group
may have an independent value and is not necessarily a
classic ‘complication’. Patients with long-term pacing
seem to have a similar outcome as those without pacing
following ASA (31, 33). Other peri-procedural compli-
cations have a significantly lower frequency. Peri-
procedural ventricular arrhythmia was found in 0.02%
and LAD dissection in 0.01% (22). Death is extremely rare,
with rates of one in 874 (22), two in 177 (12) (both in
cardiogenic shock before ASA), three in 459 (32) and zero
in 465 reported (13).Results
Survival
HCM patients with resting LVOT obstruction have a
higher mortality than matched HCM patients without a
gradient (2). Recent case series have suggested that
removing the gradient may have a beneficial effect on
survival (12, 13, 34, 35). These are results from observa-
tional studies rather than randomised controlled trials
must therefore be taken in context. The observations will,
however, go some way to reassuring operators that the
iatrogenic scar of ASA does not increase mortality in the
medium term.Risk of ventricular arrhythmia
The fears regarding a pro-arrhythmic risk from the
iatrogenic scar formed by ASA do not appear to have
been substantiated. There is conflicting evidence but most
case series report no increased risk of SCD, ventricular
arrhythmias or appropriate ICD therapy (12, 13, 34, 35,
36, 37), while a smaller number claim an increased risk
of ventricular arrhythmia (38, 39).R30
Figure 4
(A) Contrast filling the RV cavity. The chosen septal vessel has a connection
to the RV cavity via Thebesian veins, therefore the contrast-injected vents
directly into the RV. Any alcohol injected herein would drain into systemic
circulation and causes minimal myocardial damage. (B) Contrast high-
lighting themid-septum. This is too apical and away from the target area at
the SAM–septal contact point in the basal septum. Alcohol injection herein
would cause an infarct away from the SAM–septal contact area and hence
would have no effect on intra-cavity gradients.
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Following the breakthrough studies, multiple early
patient series were reported and summarised in a
systematic review collated in 2006 (30). In total,www.echorespract.com2959 patients were summarised from 42 published
studies, although the authors accept that some were
duplicated by involvement in more than one report.
A baseline assessment revealed a mean age of 53.5 years,
an NYHA class of 2.9 despite medical therapy and peak
LVOT gradients of 65 mmHg at rest and 125 mmHg on
provocation. The mean follow-up period was just over a
year. Early mortality (defined as within 30 days) was
reported to be 1.5%, with late all-cause mortality at
0.5% (0–9.3%). NYHA status improved significantly to 1.2
(P!0.001). A reduction in angina burden was also
observed; the Canadian Cardiovascular Society score
reduced from 1.9 to 0.4 (P!0.001). Echocardiographic
gradients reduced to 15 mmHg at rest and 31 mmHg on
provocation (both P!0.001). Repeat procedures were
required in 7% of patients.
A 2011 report from the Multicentre North American
registry detailed procedures in 874 patients. All had a
resting gradient of R30 mmHg or provocable gradient of
R60 mmHg with advanced symptoms of exertional
dyspnoea and/or angina despite medical therapy (40).
The mean follow-up duration was 26 months. Seventy-
eight per cent of patients suffered NYHA class III or IV
dyspnoea before the procedure, with a gradient measuring
70 mmHg at rest and 99 mmHg on provocation. Following
ASA, 72.5% of patients were classified as NYHA class I, 23%
as class II, 3.9% as class III and 0.65% as class IV. A repeat
procedure was required in 12.8% of patients. A mean of
peak resting gradients reduced to 35 mmHg post-
procedure. The Scandinavian multicentre study included
279 patients with similar results, with NYHA III/IV
breathlessness reduced from 94 to 21% and outflow tract
gradients falling from 58 to 12 mmHg. Those persisting
with NYHA III/IV breathlessness had a high prevalence of
co-morbidities including chronic obstructive pulmonary
disease and valve disease (25).
A number of series of medium-term results are now
available, with time periods ranging from 25 to 141
months (12, 13, 22, 35, 36, 41, 42, 43, 44, 45, 46)
(Table 3). Improvement in dyspnoea is observed in
most, with a clear trend towards lower LVOT gradients.
The procedure does not provide uniform improvement
for all, however, with a large recent series displaying a
mean post-procedure resting gradient of 35 mmHg (22)
(a gradient some would claim justifies repeat treatment)
and persistent NYHA class III dyspnoea in 21% (25). There
is therefore scope for improvement in treatment and
subsequent outcomes for HCM patients with LVOT
obstruction refractory to medical therapy.R31
Table 3 Long-term results from observational studies post-ASA.
Author Year
Follow-up
(months) n
Age at
ASA (years)
Pre Post Complications
NYHA
Rest grad
(mmHg) NYHA
Rest grad
(mmHg)
Death at
ASA (%)
Death at
follow-up (%)
Death cardiac
cause (%)
Seggewiss 2007 58 100 53 2.8 76 1.6 0 1 4 2
Kwon 2008 96 55 63 96% R3 70 17% R3 31 24 2
Fernandes 2008 55 579 54 2.8 77 1.4 !10 9 4
Kuhn 2008 25 329 58 54 21 1.8 8.9 3
Lyne 2010 141 12 49 2.7 70 1 3 0 24 16
Klopotowski 2010 111 61 48 0 5 1.6
Jensen 2011 42 77 61 97% R3 60 9% R3 12 0 16 6.5
Nagueh 2011 26 874 55 78% R3 70 4.5%R3 35 9.3 2.8
Jensen 2011 44 279 59 94% R3 58 21% R3 12 0.3 12.2
Sorajja 2012 68 177 64 100% R3 73 67% Z1 11 1.1 14.7 2.8
Jensen 2013 100 465 56 86% R3 60 8% R3 6 0 9 4
Veselka 2014 3 436 57 2.8 88 1.6 21 0.2 0.7
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According to the 2011 ACC/ACCF guidelines, surgical
myectomy remains the treatment of choice for HOCM
with symptoms of heart failure. Surgery has a class IIa
recommendation, ASA is class IIb (11). This is based on
excellent survival, symptom resolution, abolition of
gradient and low operative mortality at centres of
excellence (47).
Meta-analyses have evaluated non-randomised
studies comparing ASA and myectomy at individual
institutions (48, 49). The age of the ASA groups tend to
be higher than the myectomy group. Baseline NYHA
status and echocardiographic characteristics were com-
parable between groups. Symptom improvement was
similar. The only significant differences to come out of
detailed statistical analysis were a higher incidence of
pacemaker implantation and RBBB in the ASA group, and
a small, yet significantly higher, residual LVOT gradient
in the ASA group (50).
Owing to limited patient populations, a randomised
controlled study to compare mortality benefit between
ASA and myectomy will likely never be performed (51).Alternative methods of non-surgical septal
reduction therapy
Alternative methods of inducing damage to the target
myocardium that have been explored include injection of
glue (52, 53), injection of microspheres (53) and coil
embolisation (54, 55). All of these methods damage
myocardium by ischaemia. The rich collateralisation of
the septum may explain the difficulties in effecti-
vely reducing long-term gradients by ischaemia alone.www.echorespract.comThese therapies have not been adopted due to the limited
impact on gradients long term.
A significant limitation of ASA is reliance on coronary
anatomy to provide access to a target for ablation. Up to
15% of patients have no septal vessel suitable for injection,
due to inability to identify or instrument an artery
supplying the basal hypertrophy at the SAM–septal
contact point (46, 56, 57). Endocardial radiofrequency
ablation has been used to deliver damage directly to the
endocardial surface of the LV basal septum and bypass this
reliance (58, 59, 60).
Lawrenz et al. (59) performed Endocardial Radio
frequency Ablation of Septal Hypertrophy (ERASH) in a
cohort of 19 adults, eight of whom had ineffective ASA due
to inappropriate coronary anatomy. All patients were
offered, and declined, surgery. Ablation was performed
from the RV septum in ten patients and LV septum in nine
patients. Although follow-up imaging showed a minor
reduction in the magnitude of septal hypertrophy, 22.6–
21.4 mm, deep scars were visible, up to 28 mm, within the
septum on cardiac MRI in some. This is in contrast to ASA,
where a more marked change in the septal thickness in
diastole is observed. Despite a modest effect on septal width,
a reduction in resting gradients of 77.7–26.5 mmHg and
provoked gradients of 157.5–64.2 mmHg was observed.
NYHA status reduced from a mean of 3.0–1.7 (59).
Reduction of septal thickening in systole is proposed
to be responsible for the reduced gradient. This akinesia
of the basal septum prevents narrowing of the LVOT
in systole, reducing SAM and therefore obstruction. The
flexibility of ERASH appeals to physicians dealing with
HOCM, and early results are comparable to results of
early ASA series (61). With a clear learning curve forR32
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promise for ERASH.Conclusion
ASA provides relief of symptoms attributable to LVOT
obstruction in the majority of patients. The success of ASA
relies upon appropriate patient selection. While initially
viewed as an alternative to myectomy only in patients
unfit for surgery, the balance of preference has changed for
some operators (63, 64, 65). The improved outcomes of
ASA are comparable to myectomy (48, 50), the compli-
cation rate has much improved and its availability is much
more widespread. Medium-term survival is better than
matched HOCM controls and even better than general
population-matched controls in some series (12, 35, 66).
While ASA can provide relief to the majority of
appropriately selected HOCM patients, up to 25–30% of
patients in the largest series are still significantly sympto-
matic or have persisting LVOT gradients O30 mmHg
(22, 25). A further 5–8% of patients selected for ASA
cannot undergo the procedure due to limitations of septal
arterial supply (46, 56). Few changes have been made in
the last decade and developments in the procedure may
be required to improve patient outcome.
Newer methods ofnon-surgical septal reduction therapy
(NSRT) therapy may provide greater options for specific
subsets of patients within the HOCM cohort (53, 55, 59, 60)
and, as these procedures develop, they may well provide
a valuable adjunct to the management of HOCM patients.Supplementary data
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